THE WOODLANDS, Texas--(BUSINESS WIRE)--
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company
developing personalized immunotherapies for autoimmune disorders,
including multiple sclerosis (MS) and Neuromyelitis Optica (NMO), today
announced that Neil K. Warma, the Company’s President and Chief
Executive Officer, has been invited to present at the Cleveland Clinic’s
12th Annual Medical Innovation Summit, taking place October
26-29, 2014, in Cleveland, Ohio.
Opexa’s presentation is part of the Ground Waves showcase and
will take place on Wednesday, October 29 at 9:15 am ET at the Cleveland
Convention Center in Room 26.
Cleveland Clinic's 12th Annual
Medical Innovation Summit will bring together more than 1,500
executives, investors, entrepreneurs and clinicians to examine the
latest innovations in cancer treatment and personalized medicine. The
Summit will feature a large variety of healthcare stakeholders from
executives in pharmaceuticals, diagnostics and devices to information
technology leaders, payers, investors, and entrepreneurs who will
discuss the most promising market-ready therapies. The Summit, titled,
"Now, it's Personal" will take a deep look at how targeted, personalized
therapies are changing the game in medicine.
Ground Waves is a two-day showcase taking place as part of the
Medical Innovation Summit that will present a wide array of companies
making waves and looking to shake up the status quo in cancer treatment
and personalized medicine.
About Opexa
Opexa is a biopharmaceutical company developing personalized
immunotherapies with the potential to treat major illnesses, including
multiple sclerosis (MS) as well as other autoimmune diseases such as
neuromyelitis optica (NMO). These therapies are based on Opexa’s
proprietary T-cell technology. The Company’s leading therapy candidate,
Tcelna®, is a personalized T-cell immunotherapy that is in a
Phase IIb clinical development program (the Abili-T trial) for the
treatment of Secondary Progressive MS. Tcelna is derived from T-cells
isolated from the patient’s peripheral blood, expanded ex vivo,
and reintroduced into the patients via subcutaneous injections. This
process triggers a potent immune response against specific subsets of
autoreactive T-cells known to attack myelin. Opexa’s mission is to lead
the field of Precision Immunotherapy® by aligning the
interests of patients, employees and shareholders.
For more information visit the Opexa Therapeutics website at www.opexatherapeutics.com.
Source: Opexa Therapeutics, Inc.